The pharmacological agent outperforms current drugs in most of cases, show multiple experiments
A new pharmacological agent demonstrates promising results for the prevention of a wide range of heart rhythm disorders, including both cardiac and brain injury-induced arrhythmias. Furthermore, the compound (SS-68) demonstrates significant activity in conditions of reduced blood flow to the heart caused by obstructed arteries.
The study, conducted by a research team led by Dr Saida Bogus of the Kuban State Medical University in Russia, is published in the open-access journal Research Results in Pharmacology.
Each year, more than 17 million people from around the globe (mostly Europe and the USA) die of cardiovascular diseases and related complications, according to the World Health Organization. In Russia, about 3 out of 1,000 people suffer from the most common and malignant heart rhythm disorder: atrial fibrillation (AF), where the count is expected to at least double in the next 30 years. While sometimes lacking symptoms, atrial fibrillation could generally be recognised by a racing, irregular heartbeat, dizziness, fatigue, shortness of breath and chest pain, thereby largely compromising the quality of one’s life. The disorder could also lead to various complications, including dementia, stroke and heart failure.
Currently, the drugs administered to AF patients have major deficiencies, including narrow therapeutic windows, which means that even minimal imprecision in the dosage could result in unacceptable toxicity. Hence, patients need to be closely monitored and have their doses adjusted on a regular basis.
In their study, the team turned to the aminoindole derivatives to look for an alternative compound. This chemical group has already shown a significant potential in terms of cardio-pharmacological activity.
Having tested the SS-68 compound on multiple occasions in different animals, the researchers report that it has a pronounced antiarrhythmic effect and is able to bring the electrical activity of the heart back to normal and, in most cases, outperforming the reference drugs used in clinical practice: amiodarone, lidocaine, aymaline, ethacizine, etmozine and quinidine anaprilin.
Further, in brain injury-induced arrhythmias, the compound was found to reduce the episodes of epilepsy. It was also observed to have a positive effect in clogged blood vessels where it is reported to have successfully increased the coronary blood flow. In addition, the compound managed to decrease the area of necrosis in the heart tissue caused by a heart attack.
“To date, there have been significant achievements of Russian and foreign pharmacologists, chemists and clinicians in creating and introducing into the practical medicine a number of antiarrhythmic drugs different by their chemical structure, nature, spectrum, activity and mechanism of action; nevertheless, one of the most important tasks of modern pharmacology is searching for and developing new highly active substances of the corresponding action,” explain the scientists.
“Special attention should be paid to an in-depth study of the molecular mechanisms of action of this compound,” they conclude.
A paper looking further into the molecular mechanisms of the antiarrhythmic action of SS-68 prepared by the same research team is currently in press with Research Results in Pharmacology.
Learn more: New promising compound against heart rhythm disorders and clogged arteries
The Latest on: Pharmacological agent
[google_news title=”” keyword=”pharmacological agent” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Pharmacological agent
- Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Conditionon May 9, 2024 at 5:24 am
There are extremely limited options for FAP patients, and if untreated, it leads to colorectal cancer 100% of the time. Without any FDA approved drugs, the only treatment option today is the removal ...
- The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headacheon May 7, 2024 at 5:00 pm
Studies suggest that flunarizine and sodium valproate might be effective prophylactic antimigraine agents. [92] Onabotulinum toxin-A is approved for headache prophylaxis in adults with chronic ...
- The Pathophysiological and Pharmacological Basis of Current Drug Treatment of Migraine Headacheon May 6, 2024 at 4:59 pm
for acute severe migraine and pharmacological agents for prophylaxis of migraine. Sumatriptan, naratriptan and others, referred to as 'triptans', are the mainstay for acute treatment of migraine.
- The Interconnection Between Insulin Resistance and Cardiovascular Risk: Unveiling the Complex Relationshipon April 30, 2024 at 4:18 am
In the intricate web of human physiology, the relationship between insulin resistance and cardiovascular risk stands as a critical nexus. As our understanding deepens, it becomes ...
- Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)on April 26, 2024 at 7:30 am
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in non-dilutive grant funding ...
- Capital One Initiates Coverage of Heron Therapeutics (HRTX) with Overweight Recommendationon April 23, 2024 at 10:51 am
Fintel reports that on April 23, 2024, Capital One initiated coverage of Heron Therapeutics (NasdaqCM:HRTX) with a Overweight recommendation. Analyst Price Forecast Suggests 175.68% Upside As of April ...
- Chapter 4: - Pharmacological Properties of Selected Dopamine Receptor Blocking Agentson April 1, 2024 at 9:17 pm
Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not ...
- Further Evaluation of the Tyramine Test for Pheochromocytomaon March 27, 2024 at 5:01 pm
The purpose of this report is to update the available information on tyramine as a diagnostic agent in pheochromocytoma and to place in perspective the role of pharmacologic tests in the diagnosis ...
- RSC Medicinal Chemistryon July 18, 2023 at 3:32 am
To be suitable for publication these must exhibit significant potential as new pharmacological agents, tools, probes or potential drugs. Modifications of known chemical entities or biotherapeutic ...
via Bing News